Aprotinin counteracts heparin-induced inhibition of platelet contractile force

Marcus E. Carr, Sheryl L. Carr, Veronica Roa, Kathleen A. McCardell, Philip E. Greilich

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Aprotinin interferes with heparin binding to platelets and decreases blood loss during cardiopulmonary bypass (CPB). Heparin abolishes platelet force during CPB, and the extent of platelet force recovery after protamine administration appears to correlate with blood loss. This study assessed the effect of aprotinin on heparin suppression of platelet force. Methods: Platelet force was measured using the Hemodyne® Hemostasis Analyzer. Clots were formed from platelet-rich plasma (PRP) by the addition of batroxobin and 10 mM CaCl2. Clotting conditions included pH 7.4, ionic strength 0.15 M, fibrinogen level 1 mg/ml and 75,000 platelets/μl. Results: After 1200 s of clotting, force was reduced from 7110±1190 to 450±450 dyn by 0.2 U/ml of heparin. Platelet force in aprotinin [20 μg/ml (140 KIU/ml)] containing PRP was not suppressed by heparin addition (7480±2410 dyn). Aprotinin [40 μg/ml (280 KIU/ml)] addition to previously heparinized plasma counteracted heparin force suppression. Aprotinin (40 μg/ml) increased platelet force from 5630 to 11,138±562 in PRP devoid of heparin. Aprotinin did not affect thrombin activity, fibrin structure, platelet aggregation or secretion. Conclusions: Aprotinin counteracts heparin suppression of platelet force and enhances platelet force in the absence of heparin. Aprotinin-heparin-platelet interactions may help explain aprotinin's ability to reduce blood loss during CPB.

Original languageEnglish (US)
Pages (from-to)161-168
Number of pages8
JournalThrombosis Research
Volume108
Issue number2-3
DOIs
StatePublished - Nov 1 2002

Fingerprint

Aprotinin
Heparin
Blood Platelets
Platelet-Rich Plasma
Cardiopulmonary Bypass
Batroxobin
Protamines
Hemostasis
Fibrin
Platelet Aggregation
Thrombin
Osmolar Concentration
Fibrinogen

Keywords

  • Aprotinin
  • Cardiopulmonary bypass
  • Clot retraction
  • Heparin
  • Platelet contractile force
  • Platelet dysfunction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Aprotinin counteracts heparin-induced inhibition of platelet contractile force. / Carr, Marcus E.; Carr, Sheryl L.; Roa, Veronica; McCardell, Kathleen A.; Greilich, Philip E.

In: Thrombosis Research, Vol. 108, No. 2-3, 01.11.2002, p. 161-168.

Research output: Contribution to journalArticle

Carr, Marcus E. ; Carr, Sheryl L. ; Roa, Veronica ; McCardell, Kathleen A. ; Greilich, Philip E. / Aprotinin counteracts heparin-induced inhibition of platelet contractile force. In: Thrombosis Research. 2002 ; Vol. 108, No. 2-3. pp. 161-168.
@article{06b190507ca04153b0c4a9f6fa28af66,
title = "Aprotinin counteracts heparin-induced inhibition of platelet contractile force",
abstract = "Background: Aprotinin interferes with heparin binding to platelets and decreases blood loss during cardiopulmonary bypass (CPB). Heparin abolishes platelet force during CPB, and the extent of platelet force recovery after protamine administration appears to correlate with blood loss. This study assessed the effect of aprotinin on heparin suppression of platelet force. Methods: Platelet force was measured using the Hemodyne{\circledR} Hemostasis Analyzer. Clots were formed from platelet-rich plasma (PRP) by the addition of batroxobin and 10 mM CaCl2. Clotting conditions included pH 7.4, ionic strength 0.15 M, fibrinogen level 1 mg/ml and 75,000 platelets/μl. Results: After 1200 s of clotting, force was reduced from 7110±1190 to 450±450 dyn by 0.2 U/ml of heparin. Platelet force in aprotinin [20 μg/ml (140 KIU/ml)] containing PRP was not suppressed by heparin addition (7480±2410 dyn). Aprotinin [40 μg/ml (280 KIU/ml)] addition to previously heparinized plasma counteracted heparin force suppression. Aprotinin (40 μg/ml) increased platelet force from 5630 to 11,138±562 in PRP devoid of heparin. Aprotinin did not affect thrombin activity, fibrin structure, platelet aggregation or secretion. Conclusions: Aprotinin counteracts heparin suppression of platelet force and enhances platelet force in the absence of heparin. Aprotinin-heparin-platelet interactions may help explain aprotinin's ability to reduce blood loss during CPB.",
keywords = "Aprotinin, Cardiopulmonary bypass, Clot retraction, Heparin, Platelet contractile force, Platelet dysfunction",
author = "Carr, {Marcus E.} and Carr, {Sheryl L.} and Veronica Roa and McCardell, {Kathleen A.} and Greilich, {Philip E.}",
year = "2002",
month = "11",
day = "1",
doi = "10.1016/S0049-3848(02)00403-6",
language = "English (US)",
volume = "108",
pages = "161--168",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "2-3",

}

TY - JOUR

T1 - Aprotinin counteracts heparin-induced inhibition of platelet contractile force

AU - Carr, Marcus E.

AU - Carr, Sheryl L.

AU - Roa, Veronica

AU - McCardell, Kathleen A.

AU - Greilich, Philip E.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Background: Aprotinin interferes with heparin binding to platelets and decreases blood loss during cardiopulmonary bypass (CPB). Heparin abolishes platelet force during CPB, and the extent of platelet force recovery after protamine administration appears to correlate with blood loss. This study assessed the effect of aprotinin on heparin suppression of platelet force. Methods: Platelet force was measured using the Hemodyne® Hemostasis Analyzer. Clots were formed from platelet-rich plasma (PRP) by the addition of batroxobin and 10 mM CaCl2. Clotting conditions included pH 7.4, ionic strength 0.15 M, fibrinogen level 1 mg/ml and 75,000 platelets/μl. Results: After 1200 s of clotting, force was reduced from 7110±1190 to 450±450 dyn by 0.2 U/ml of heparin. Platelet force in aprotinin [20 μg/ml (140 KIU/ml)] containing PRP was not suppressed by heparin addition (7480±2410 dyn). Aprotinin [40 μg/ml (280 KIU/ml)] addition to previously heparinized plasma counteracted heparin force suppression. Aprotinin (40 μg/ml) increased platelet force from 5630 to 11,138±562 in PRP devoid of heparin. Aprotinin did not affect thrombin activity, fibrin structure, platelet aggregation or secretion. Conclusions: Aprotinin counteracts heparin suppression of platelet force and enhances platelet force in the absence of heparin. Aprotinin-heparin-platelet interactions may help explain aprotinin's ability to reduce blood loss during CPB.

AB - Background: Aprotinin interferes with heparin binding to platelets and decreases blood loss during cardiopulmonary bypass (CPB). Heparin abolishes platelet force during CPB, and the extent of platelet force recovery after protamine administration appears to correlate with blood loss. This study assessed the effect of aprotinin on heparin suppression of platelet force. Methods: Platelet force was measured using the Hemodyne® Hemostasis Analyzer. Clots were formed from platelet-rich plasma (PRP) by the addition of batroxobin and 10 mM CaCl2. Clotting conditions included pH 7.4, ionic strength 0.15 M, fibrinogen level 1 mg/ml and 75,000 platelets/μl. Results: After 1200 s of clotting, force was reduced from 7110±1190 to 450±450 dyn by 0.2 U/ml of heparin. Platelet force in aprotinin [20 μg/ml (140 KIU/ml)] containing PRP was not suppressed by heparin addition (7480±2410 dyn). Aprotinin [40 μg/ml (280 KIU/ml)] addition to previously heparinized plasma counteracted heparin force suppression. Aprotinin (40 μg/ml) increased platelet force from 5630 to 11,138±562 in PRP devoid of heparin. Aprotinin did not affect thrombin activity, fibrin structure, platelet aggregation or secretion. Conclusions: Aprotinin counteracts heparin suppression of platelet force and enhances platelet force in the absence of heparin. Aprotinin-heparin-platelet interactions may help explain aprotinin's ability to reduce blood loss during CPB.

KW - Aprotinin

KW - Cardiopulmonary bypass

KW - Clot retraction

KW - Heparin

KW - Platelet contractile force

KW - Platelet dysfunction

UR - http://www.scopus.com/inward/record.url?scp=0036878199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036878199&partnerID=8YFLogxK

U2 - 10.1016/S0049-3848(02)00403-6

DO - 10.1016/S0049-3848(02)00403-6

M3 - Article

C2 - 12590953

AN - SCOPUS:0036878199

VL - 108

SP - 161

EP - 168

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 2-3

ER -